“Vascular calcification: hard disease in heart. A rocky road towards diagnosis
and intervention.”


OSLO, NORWAY AND EDISON, NJ (25 OCT 2018) — On Friday 12 October 2018, an international
symposium was hosted at the University of Maastricht, The Netherlands, where four presentations were
given examining the role of arterial calcification and the impact of Vitamin K2. NattoPharma ASA and
others sponsored the event.

“Over the last 12 years, NattoPharma has heavily invested in research that has undeniably demonstrated
that Vitamin K2 results in stronger bones,” says Frode Bohan, Chairman of the Board with NattoPharma.
“However, the most recent research has had the biggest impact: namely, the cardiovascular implications
of Vitamin K2 as a mitigator of the disasterous role of arterial and soft tissue calcification.”

Observational and intervention studies have shown that populations who consume high concentrations of
Vitamin K2 have more flexible arteries and stronger bones. Now, the evidence is mounting confirming that
K2 can positively impact populations that are prone to calcification, such as chronic kidney disease (CKD)
patients and those with existing coronary artery calcification (CAC) and arterial valve calcification (AVC).

“This clearly demonstrates NattoPharma’s ongoing commitment to promote science-based education,”
Bohan continues.

The lectures at the symposium consisted of two basic and two clinical presentations:

• Prof. Dr. Cathy Shanahan, Professor of Cellular Signaling, Cardiovascular Division, King’s College London:
“Are you as old as your arteries?”
• Prof. Dr. Willi Jahnen-Dechent, Helmholtz-Institute for Biomedical Engineering, Biointerface Laboratory,
RWTH Aachen University Medical Faculty: “Mud in the blood: protein-mineral complexes involved in
mineralization and calcification”
• Prof. Dr. Marc Vervloet, Nephrologist, Department of Nephrology, Aumc Amsterdam: “A Clinical
Perspective on Vascular Calcification in Kidney Disease”
• Prof. Dr. Bram Kroon, Internist – Vascular Medicine, MUMC + Maastricht: “Treatment Perspectives of
Vascular Calcifications in Cardiovascular Patients”

In addition to NattoPharma, other sponsors of the event were TGMontgomery, IDS, Omicron, Eqology, and

After the symposium, Prof. Dr. Leon Schurgers, Professor of Biochemistry of Vascular Calcification and Vice
Chair of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Department of Biochemistry,
University of Maastricht, gave his inaugural lecture “Vascular calcification: hard disease in the heart”.


About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development.
NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best
documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical
substantiation, and international patents granted and pending; and now the new MenaQ7® Full Spectrum,
which delivers menaquinones 6, 7, and 9. The company has a multi-year research and development
program to substantiate and discover the health benefits of Vitamin K2 for applications in the marketplace
for functional food and dietary supplements. With a global presence, the company established its North
American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more
information, visit www.nattopharma.com or www.menaq7.com.

For more information, please contact:
Kate Quackenbush, NattoPharma Director of Communications
Phone: 609-643-0749 x 220 E-mail: kate.quackenbush@nattopharma.com